TSPO PET brain inflammation imaging: a transdiagnostic systematic review and meta-analysis of 156 case-control studies
TSPO PET brain inflammation imaging: a transdiagnostic systematic review and meta-analysis of 156 case-control studies
Introduction: The 18-kDa translocator protein (TSPO) is increasingly recognized as a molecular target for PET imaging of inflammatory responses in various central nervous system (CNS) disorders. However, the reported sensitivity and specificity of TSPO PET to identify brain inflammatory processes appears to vary greatly across disorders, disease stages, and applied quantification methods. To advance TSPO PET as a potential biomarker to evaluate brain inflammation and anti-inflammatory therapies, a better understanding of its applicability across disorders is needed. We conducted a transdiagnostic systematic review and meta-analysis of all in vivo human TSPO PET imaging case-control studies in the CNS. Specifically, we investigated the direction, strength, and heterogeneity associated with the TSPO PET signal across disorders in pre-specified brain regions, and explored the demographic and methodological sources of heterogeneity. Methods: We searched for English peer-reviewed articles that reported in vivo human case-control TSPO PET differences. We extracted the demographic details, TSPO PET outcomes, and technical variables of the PET procedure. A random-effects meta-analysis was applied to estimate case-control standardized mean differences (SMD) of the TSPO PET signal in the lobar/whole-brain cortical grey matter (cGM), thalamus, and cortico-limbic circuitry between different illness categories. Heterogeneity was evaluated with the I
2 statistic and explored using subgroup and meta-regression analyses for radioligand generation, PET quantification method, age, sex, and publication year. Significance was set at the False Discovery Rate (FDR)-corrected P < 0.05. Results: 156 individual case-control studies were included in the systematic review, incorporating data for 2381 healthy controls and 2626 patients. 139 studies documented meta-analysable data and were grouped into 11 illness categories. Across all the illness categories, we observed a significantly higher TSPO PET signal in cases compared to controls for the cGM (n = 121 studies, SMD = 0.358, P
FDR < 0.001, I
2 = 68%), with a significant difference between the illness categories (P = 0.004). cGM increases were only significant for Alzheimer's disease (SMD = 0.693, P
FDR < 0.001, I
2 = 64%) and other neurodegenerative disorders (SMD = 0.929, P
FDR < 0.001, I
2 = 73%). Cortico-limbic increases (n = 97 studies, SMD = 0.541, P < 0.001, I
2 = 67%) were most prominent for Alzheimer's disease, mild cognitive impairment, other neurodegenerative disorders, mood disorders and multiple sclerosis. Thalamic involvement (n = 79 studies, SMD = 0.393, P < 0.001, I
2 = 71%) was observed for Alzheimer's disease, other neurodegenerative disorders, multiple sclerosis, and chronic pain and functional disorders (all P
FDR < 0.05). Main outcomes for systemic immunological disorders, viral infections, substance use disorders, schizophrenia and traumatic brain injury were not significant. We identified multiple sources of between-study variance to the TSPO PET signal including a strong transdiagnostic effect of the quantification method (explaining 25% of between-study variance; V
T-based SMD = 0.000 versus reference tissue-based studies SMD = 0.630; F = 20.49, df = 1;103, P < 0.001), patient age (9% of variance), and radioligand generation (5% of variance). Conclusion: This study is the first overarching transdiagnostic meta-analysis of case-control TSPO PET findings in humans across several brain regions. We observed robust increases in the TSPO signal for specific types of disorders, which were widespread or focal depending on illness category. We also found a large and transdiagnostic horizontal (positive) shift of the effect estimates of reference tissue-based compared to V
T-based studies. Our results can support future studies to optimize experimental design and power calculations, by taking into account the type of disorder, brain region-of-interest, radioligand, and quantification method.
Alzheimer's disease, Brain imaging, Depression, Meta-analysis, Microglia, Multiple sclerosis, Neuroinflammation, Parkinson's disease, Schizophrenia, TSPO PET
415-431
De Picker, Livia J.
8646e4e2-34c9-4156-98ec-fed01231d8ab
Morrens, Manuel
08a72609-a3b3-4318-a7db-ee7e173b52ac
Branchi, Igor
ecf1c530-7b9b-4715-88eb-7dca80bf9ae3
Haarman, Bartholomeus C.M.
6f77f787-30b5-4ad5-8d3d-061b642c8efb
Terada, Tatsuhiro
3f8d28c8-824e-42ee-8f38-b2ef53aaa0bd
Kang, Min Su
b70603dd-9649-4ff4-93ba-014de1766a96
Boche, Delphine
bdcca10e-6302-4dd0-919f-67218f7e0d61
Tremblay, Marie-Eve
6488ad6e-c7d4-44a1-befc-25521bb8106c
Leroy, Claire
3aab6298-a630-4fe2-968e-409d85fe09ba
Bottlaender, Michel
7ec76930-cf42-4f7b-8801-fbb3789eabed
Ottoy, Julie
dfa69539-a586-4637-9d91-c0acb5a10a29
October 2023
De Picker, Livia J.
8646e4e2-34c9-4156-98ec-fed01231d8ab
Morrens, Manuel
08a72609-a3b3-4318-a7db-ee7e173b52ac
Branchi, Igor
ecf1c530-7b9b-4715-88eb-7dca80bf9ae3
Haarman, Bartholomeus C.M.
6f77f787-30b5-4ad5-8d3d-061b642c8efb
Terada, Tatsuhiro
3f8d28c8-824e-42ee-8f38-b2ef53aaa0bd
Kang, Min Su
b70603dd-9649-4ff4-93ba-014de1766a96
Boche, Delphine
bdcca10e-6302-4dd0-919f-67218f7e0d61
Tremblay, Marie-Eve
6488ad6e-c7d4-44a1-befc-25521bb8106c
Leroy, Claire
3aab6298-a630-4fe2-968e-409d85fe09ba
Bottlaender, Michel
7ec76930-cf42-4f7b-8801-fbb3789eabed
Ottoy, Julie
dfa69539-a586-4637-9d91-c0acb5a10a29
De Picker, Livia J., Morrens, Manuel, Branchi, Igor, Haarman, Bartholomeus C.M., Terada, Tatsuhiro, Kang, Min Su, Boche, Delphine, Tremblay, Marie-Eve, Leroy, Claire, Bottlaender, Michel and Ottoy, Julie
(2023)
TSPO PET brain inflammation imaging: a transdiagnostic systematic review and meta-analysis of 156 case-control studies.
Brain, Behavior and Immunity, 113, , [YBRBI_5170].
(doi:10.1016/j.bbi.2023.07.023).
Abstract
Introduction: The 18-kDa translocator protein (TSPO) is increasingly recognized as a molecular target for PET imaging of inflammatory responses in various central nervous system (CNS) disorders. However, the reported sensitivity and specificity of TSPO PET to identify brain inflammatory processes appears to vary greatly across disorders, disease stages, and applied quantification methods. To advance TSPO PET as a potential biomarker to evaluate brain inflammation and anti-inflammatory therapies, a better understanding of its applicability across disorders is needed. We conducted a transdiagnostic systematic review and meta-analysis of all in vivo human TSPO PET imaging case-control studies in the CNS. Specifically, we investigated the direction, strength, and heterogeneity associated with the TSPO PET signal across disorders in pre-specified brain regions, and explored the demographic and methodological sources of heterogeneity. Methods: We searched for English peer-reviewed articles that reported in vivo human case-control TSPO PET differences. We extracted the demographic details, TSPO PET outcomes, and technical variables of the PET procedure. A random-effects meta-analysis was applied to estimate case-control standardized mean differences (SMD) of the TSPO PET signal in the lobar/whole-brain cortical grey matter (cGM), thalamus, and cortico-limbic circuitry between different illness categories. Heterogeneity was evaluated with the I
2 statistic and explored using subgroup and meta-regression analyses for radioligand generation, PET quantification method, age, sex, and publication year. Significance was set at the False Discovery Rate (FDR)-corrected P < 0.05. Results: 156 individual case-control studies were included in the systematic review, incorporating data for 2381 healthy controls and 2626 patients. 139 studies documented meta-analysable data and were grouped into 11 illness categories. Across all the illness categories, we observed a significantly higher TSPO PET signal in cases compared to controls for the cGM (n = 121 studies, SMD = 0.358, P
FDR < 0.001, I
2 = 68%), with a significant difference between the illness categories (P = 0.004). cGM increases were only significant for Alzheimer's disease (SMD = 0.693, P
FDR < 0.001, I
2 = 64%) and other neurodegenerative disorders (SMD = 0.929, P
FDR < 0.001, I
2 = 73%). Cortico-limbic increases (n = 97 studies, SMD = 0.541, P < 0.001, I
2 = 67%) were most prominent for Alzheimer's disease, mild cognitive impairment, other neurodegenerative disorders, mood disorders and multiple sclerosis. Thalamic involvement (n = 79 studies, SMD = 0.393, P < 0.001, I
2 = 71%) was observed for Alzheimer's disease, other neurodegenerative disorders, multiple sclerosis, and chronic pain and functional disorders (all P
FDR < 0.05). Main outcomes for systemic immunological disorders, viral infections, substance use disorders, schizophrenia and traumatic brain injury were not significant. We identified multiple sources of between-study variance to the TSPO PET signal including a strong transdiagnostic effect of the quantification method (explaining 25% of between-study variance; V
T-based SMD = 0.000 versus reference tissue-based studies SMD = 0.630; F = 20.49, df = 1;103, P < 0.001), patient age (9% of variance), and radioligand generation (5% of variance). Conclusion: This study is the first overarching transdiagnostic meta-analysis of case-control TSPO PET findings in humans across several brain regions. We observed robust increases in the TSPO signal for specific types of disorders, which were widespread or focal depending on illness category. We also found a large and transdiagnostic horizontal (positive) shift of the effect estimates of reference tissue-based compared to V
T-based studies. Our results can support future studies to optimize experimental design and power calculations, by taking into account the type of disorder, brain region-of-interest, radioligand, and quantification method.
Text
1-s2.0-S0889159123002167-main
- Version of Record
More information
Accepted/In Press date: 30 July 2023
e-pub ahead of print date: 3 August 2023
Published date: October 2023
Additional Information:
Funding Information:
Dr. Ottoy is funded by the Alzheimer’s Association ( AARF-21-848556 ). Dr. Tremblay is a Tier 2 Canada Research Chair in Neurobiology of Aging and Cognition. Prof Boche’s study on TSPO is funded by the Alzheimer’s Research United Kingdom ( ARUK-PhD2019-016 ).
Funding Information:
Dr. Ottoy is funded by the Alzheimer's Association (AARF-21-848556). Dr. Tremblay is a Tier 2 Canada Research Chair in Neurobiology of Aging and Cognition. Prof Boche's study on TSPO is funded by the Alzheimer's Research United Kingdom (ARUK-PhD2019-016).
Publisher Copyright:
© 2023 The Author(s)
Keywords:
Alzheimer's disease, Brain imaging, Depression, Meta-analysis, Microglia, Multiple sclerosis, Neuroinflammation, Parkinson's disease, Schizophrenia, TSPO PET
Identifiers
Local EPrints ID: 481210
URI: http://eprints.soton.ac.uk/id/eprint/481210
ISSN: 0889-1591
PURE UUID: 74bd4240-be7c-408e-8472-dee9aef7d18d
Catalogue record
Date deposited: 18 Aug 2023 16:43
Last modified: 18 Mar 2024 02:52
Export record
Altmetrics
Contributors
Author:
Livia J. De Picker
Author:
Manuel Morrens
Author:
Igor Branchi
Author:
Bartholomeus C.M. Haarman
Author:
Tatsuhiro Terada
Author:
Min Su Kang
Author:
Marie-Eve Tremblay
Author:
Claire Leroy
Author:
Michel Bottlaender
Author:
Julie Ottoy
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics